Thu 20 Aug 2026
All official websites of government entities in the Kingdom of Saudi Arabia end with.gov.sa.
Ensure the website is using the HTTPS protocol.
Registered with the Digital Government Authority under number:
| Study Title | Study Sponsor | Status | Study Drug | Trial Phase | Study Protocol Number | Site |
|---|---|---|---|---|---|---|
| "A Phase IIIb, Single-arm Study to Evaluate the Safety and Immunogenicity ofArabio Meningococcal ACWY Conjugate Vaccine in Healthy Subjects Aged 56Years and Above in Saudi Arabia" | Arabio | Completed | Meningococcal Conjugate Vaccine (MenACWY-CRM) (Aramen) | 3b | ARA/001/16 | King Khalid University Hospital (Riyadh) |
| Intra Peritoneal Instillation of Ropivacaine with or without Dexmedetomidine for Postoperative Analgesia After Laparoscopic Sleeve Gastrectomy. A randomized controlled | King Abdullah Medical City, Makkah | Completed | Dexmedetomidine | 2 | version 4 | King Abdullah Medical City (Makkah) |
| Vitamin D Status Correction and Validation of its Potential Clinical Utility through Discovery Proteomic Analysis | Prince Mutaib Chair for Biomarkers of Osteoporosis/synergypha-rma | Completed | cholecalciferol | 3 | E-15-1667 | King Khalid University Hospital (Riyadh), King Fahad Medical City (Riyadh) |
| Open Label, Multinational, Multicenter, Real World Treatment Study of Single Agent AZD9291 for Patients with Advanced/Metastatic Epidermal Growth Factor Receptor (EGFR)T790M Mutation-Positive Non-Small Cell Lung Cancer (NSCLC) Who Have Received Prior Therapy with an EGFR Tyrosine Kinase Inhibitor(EGFR-TKI) | AstraZeneca | Completed | Osimertinib (AZD9291) | 3 | D5160C00022 | King Fahad Specialist Hospital (Dammam), King Abdulaziz Medical City NG (Riyadh) |
| A Phase III, Double-Blind, Randomised Study to Assess the Efficacy and Safety of AZD9291 versus a Standard of Care Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with Epidermal Growth Factor Receptor Mutation Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer | AstraZeneca | Terminated | Osimertinib (AZD9291) | 3 | D5160C00007 | King Faisal Specialist Hospital and Research Center (Riyadh) |
| A Randomized Trial of Influenza Vaccine to Reduce Adverse Vascular Events: A Pilot Study | McMaster University | Terminated | haemagglutinin (HA)/Inactivated Influenza Vaccine Trivalent Types A and B (Split Virion) | 3 | Version date Sep-3-2013 | King Khalid University Hospital (Riyadh) |
| Multicentre, Randomised, Controlled, Open-label Study Comparing the Efficacy and Safety of Slow Repeated IV Infusions of 2 Doses of Doxorubicin Transdrug™ (DT) (20mg/m2 and 30mg/m2) to Those of Best Standard of Care (BSC) in Patients With Advanced Hepatocellular Carcinoma (HCC) After Failure or Intolerance to Sorafenib. ReLive Study. | Onxeo | Completed | Doxorubicin | 3 | BA2011/03/04 | King Abdulaziz University Hospital (Jeddah), King Abdulaziz Medical City NG (Jeddah) |
| Phase 1 Trial of Ocular Subretinal Injection of a Recombinant Adeno-Associated Virus (rAAV2-VMD2-hMERTK) Gene Vector to Patients with Retinal Disease due to MERTK Mutations | PSCDR | Completed | rAAV2-VMD2-hMERTK | 1 | rAAV2-VMD2-hMERTK | King Faisal Specialist Hospital and Research Center (Riyadh), King Khaled Eye Specialist Hospital (Riyadh) |
| A Compartive Multicenter Study of Neoadjuvant Docetaxel/Cisplatin Followed by Concurrent Cisplatin with Radiotherapy using Intensity-Modulated Radition Therapy (IMRT) with or without Bevacizumab for Locally Advanced Nasopharyngeal Cancer | King Fahad Medical City | Terminated | Docetaxel/Cisplatin and Bevacizumab | 3 | Version 1.3 date 6 may 2012 | King Fahad Medical City (Riyadh), Prince Sultan Military Medical City (Riyadh) |
| "An open-label extension study of the long-term safety,tolerability and efficacy of Ambrisentan in subjects with inoperable chronic thromboembolic pulmonary hypertension(CTEPH)." | GSK | Terminated | Ambrisentan | 3 | 116457 | King Fahad Medical City (Riyadh) |
Last update date: 08/05/2025 at 03:17 PM Saudi Arabia time
No feedback has been submitted for this page yet.
Comments and Suggestions
For any inquiries or comments about the government services, please fill in the required information.